Table 4.
Association between SNP and chemotherapeutic response in 158 NSCLC patients treated with platinum-based chemotherapy.
| SNP | Genotype | No. patients (%) | Additive | Dominant | Recessive | ||||
|---|---|---|---|---|---|---|---|---|---|
| CR+PR | SD+PD | OR(95%CI) | p | OR(95%CI) | p | OR(95%CI) | p | ||
| rs9526814 | TT | 26 (41.9) | 39 (45.3) | 0.711 | 0.155 | 0.841 | 0.613 | 0.362 | 0.036 |
| TG | 22 (35.5) | 38 (44.2) | (0.444-1.138) | (0.430-1.645) | (0.140-0.935) | ||||
| GG | 14 (22.6) | 9 (10.5) | |||||||
CR: complete response; PR: partial response; SD: stable disease; PD: progressing disease; SNP: single nucleotide polymorphism; OR: odd ratio; CI: confidence interval.